Navigation Links
Vici Health Sciences Expands Staff and Footprint in Maryland to Meet Customer Demands
Date:12/31/2019

Vici Health Sciences announces it is breaking ground in expanding its pharmaceutical product development lab in Maryland. Emphasis will be in expanding capabilities in both oral and parenteral dosage forms. With the increased size and expanded capabilities, Vici Health Sciences will be well positioned to meet the growing demand for its pharmaceutical formulation and analytical method development services. Founded in 2016 with the aim of rapidly developing drugs to meet acute and long-term market needs, Vici currently works with over 10 different pharmaceutical companies and continues to expand its client base. The current expansion is focused on improving capabilities in manufacturing GMP clinical supplies and increases Vici’s ability to handle additional clients simultaneously.

Dr Anish Dhanarajan, CEO and co-founder stated: “We work hard to provide our clients innovative R&D solutions to bring their drugs to the market. Our clients want to develop high quality pharmaceutical drug products rapidly and clearly recognize the value we are able to provide. This expansion will allow us to meet the growing demand for our services.”

About Vici Health Sciences LLC
Vici Health Sciences (Vici) is a U.S. based pharmaceutical research and development company. Vici is focused on providing innovative, flexible, high quality, and low-cost R&D services to small and mid-sized pharmaceutical companies that need to grow their product portfolio. Vici currently focuses on oral and injectable dosage forms and operates an R&D and GMP facility capable of developing formulations, analytical methods, and manufacturing phase 1/pilot clinical supplies.

Read the full story at https://www.prweb.com/releases/vici_health_sciences_expands_staff_and_footprint_in_maryland_to_meet_customer_demands/prweb16809028.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vici Health Sciences is announcing its successful completion of initial clinical studies for its 505(b)(2) product pipeline
2. Focal Healthcare’s Fusion Bx 2.0 Targeted Prostate Biopsy Solution Receives CE Mark
3. Leading Experiential Marketing Agency, Sparks, Invests in Healthcare Marketing Firm, Bichsel Medical Marketing Group
4. Tech PR Firm ARPR Honored as a Health Care PR Agency of the Year; Grows HealthIT Practice Group 18% Quarter-Over-Quarter
5. BHIP Takes Aim at Teenagers’ Stress, Anxiety, Executive Function, Interpersonal Skills, and Overall Mental Health
6. eKare’s inSight Joins the NHS Digital Health Accelerator Program
7. Advancements Announces New Episode Focusing on Innovations in Health, Medicine, and Technology
8. MyBioGate Global Healthcare Innovation Competition Boston Preliminary Successfully Came to the Conclusion
9. Visikol Presents on Imaging 3D Cell Culture Models at the National Institute of Health
10. VetStem Biopharma, Parent Company of Personalized Stem Cells, is Approved for Stem Cell Manufacturing by the California Department of Public Health
11. Centura Health’s Innovative Patient Experience Initiative for Needle-Free Blood Draws
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2020)... ... March 04, 2020 , ... ... of recombinant antibody products and services, today announced the launch of its ... rapidly express a large number of antibodies at 80 ml scale. All ...
(Date:3/3/2020)... ... March 03, 2020 , ... Frictionless Solutions, a specialized event ... was recognized by INC. 5,000 on an annual list of America’s fastest growing ... greatly impacting their spheres of influence and experiencing considerable development. INC. 5,000’s specific ...
(Date:3/2/2020)... ... ... McBee, Moore and Vanik IP, LLC (MMV IP) has been ranked 12th ... , According to statistics compiled by Harrity Anaytics, MMV IP was listed as the ... during 2019. Technology center 1600 at the US Patent Office (“USPTO”) specializes in the ...
(Date:2/26/2020)... ... February 25, 2020 , ... Continuing its leading ... the results of its safety assessment on the biotechnologically produced 3-Fucolsyllactose (3-FL) HMO. ... milk. These complex carbohydrates are indigestible and therefore function as a prebiotic by ...
Breaking Biology Technology:
(Date:3/9/2020)... ... March 09, 2020 , ... Application ... year, as enterprises sought to achieve competitive advantage by transforming their core ... all transformation efforts delivered the intended consequences. , Application transformation refers to ...
(Date:3/5/2020)... DENVILLE, N.J. (PRWEB) , ... March 05, 2020 ... ... for sample preparation and epigenetics research, and MGI Tech (MGI), a subsidiary of ... NGS library preparation product line in the United States, Europe and Asia Pacific. ...
(Date:3/4/2020)... THE WOODLANDS, Texas (PRWEB) , ... March 04, ... ... high quality plasmid DNA-based products and services, announced it has been nominated as ... Vaccine Industry Excellence (ViE) Awards. This nomination comes as VGXI expedites manufacturing of ...
Breaking Biology News(10 mins):